1. |
Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
|
2. |
Wallace MC, Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol, 2015, 9(6): 765-779.
|
3. |
Ozer Etik D, Suna N, Boyacioglu AS. Management of hepatocellular carcinoma: prevention, surveillance, diagnosis, and staging. Exp Clin Transplant, 2017, 15(Suppl 2): 31-35.
|
4. |
Sangmala P, Chaikledkaew U, Tanwandee T, et al. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients. Asian Pac J Cancer Prev, 2014, 15(20): 8993-9004.
|
5. |
安天志, 高嵩, 靳勇, 等. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南. 介入放射学杂志, 2018, 27(12): 1117-1126.
|
6. |
Eggert T, Greten TF. Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma. Digestion, 2017, 96(1): 1-4.
|
7. |
Kim JH, Sinn DH, Shin SW, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clin Mol Hepatol, 2017, 23(1): 42-50.
|
8. |
Moschouris H, Kalokairinou-Motogna M, Vrakas S, et al. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS). Med Ultrason, 2017, 19(2): 134-142.
|
9. |
Cho YZ, Park SY, Choi EH, et al. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. Clin Mol Hepatol, 2015, 21(2): 165-174.
|
10. |
Zhong J, Su Z, Zhang Y, et al. Contrast-enhanced ultrasonography versus contrast-enhanced computed tomography for assessment of residual tumor from hepatocellular carcinoma treated with transarterial chemoembolization: a meta-analysis. J Ultrasound Med, 2018, 37(8): 1881-1890.
|
11. |
夏要友, 陆信, 王家平, 等. 超声造影在评价TACE治疗肝癌效果的临床价值研究. 昆明医科大学学报, 2013, 34(7): 44-46.
|
12. |
Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol, 2018, 211(5): 1026-1034.
|
13. |
Thaiss WM, Haberland U, Kaufmann S, et al. Dose optimization of perfusion-derived response assessment in hepatocellular carcinoma treated with transarterial chemoembolization: comparison of volume perfusion CT and iodine concentration. Acad Radiol, 2018, pii: S1076-6332(18): 30465-3.
|
14. |
Tamandl D, Waneck F, Sieghart W, et al. Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. Eur J Radiol, 2017, 90: 73-80.
|
15. |
Kloth C, Thaiss WM, K?rgel R, et al. Evaluation of texture analysis parameter for response prediction in patients with hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (DEB-TACE) using biphasic contrast-enhanced CT image data: correlation with liver perfusion CT. Acad Radiol, 2017, 24(11): 1352-1363.
|
16. |
Kaufmann S, Horger T, Oelker A, et al. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation. Eur J Radiol, 2015, 84(12): 2548-2554.
|
17. |
Wang J, Shen JL. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study. Medicine (Baltimore), 2017, 96(52): e9236.
|
18. |
Liu QY, He CD, Zhou Y, et al. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol, 2016, 22(11): 3242-3251.
|
19. |
江奇琦, 曹玉坤, 吴爱兰, 等. 能谱CT多参数成像在肝癌TACE治疗后随访中的初步研究. 临床放射学杂志, 2018, 37(3): 518-523.
|
20. |
项昆, 赵鹤亮, 郑昌英, 等. 16排螺旋CT和MRI对原发性肝癌TACE术后病灶的疗效判断价值对比. 实用癌症杂志, 2014, 29(10): 1315-1317.
|
21. |
郭永建, 黄文薮, 周斌, 等. TACE联合CT引导下射频消融治疗特殊部位小肝癌. 中华医学杂志, 2013, 93(33): 2627-2630.
|
22. |
Wu LF, Rao SX, Xu PJ, et al. Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol, 2019, 29(1): 213-223.
|
23. |
张薇薇, 宋彬, 黄子星, 等. 术前表观扩散系数预测肝癌行TACE后近期疗效的价值. 中国普外基础与临床杂志, 2015, 22(9): 1133-1136.
|
24. |
Wu XM, Wang JF, Ji JS, et al. Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther, 2017, 10: 1637-1643.
|
25. |
Chen X, Xiao E, Shu D, et al. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol, 2014, 26(1): 109-113.
|
26. |
Liang PC, Ch'ang HJ, Hsu C, et al. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatol Int, 2015, 9(2): 258-268.
|
27. |
Hsu HY, Yu MC, Lee CW, et al. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. BMC Cancer, 2017, 17(1): 742.
|
28. |
Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, et al. Prediction of post-TACE necrosis of hepatocellular carcinoma using volumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol, 2018, 28(7): 3032-3040.
|
29. |
Park S, Kim TS, Kang SH, et al. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. Medicine (Baltimore), 2018, 97(37): e12311.
|
30. |
Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics, 2014, 4(7): 736-744.
|
31. |
Kim SH, Won KS, Choi BW, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging, 2012, 46(2): 102-110.
|
32. |
彭辽河, 胡晓燕, 李杰, 等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值. 介入放射学杂志, 2012, 21(8): 636-640.
|
33. |
张韵, 黄子星, 宋彬. 肝细胞癌生物免疫治疗的影像学评价现状. 中国普外基础与临床杂志, 2018, 25(7): 867-872.
|
34. |
李天然. 肝细胞癌PET/CT研究进展. 胃肠病学和肝病学杂志, 2017, 26(11): 1201-1205.
|
35. |
柳昂, 许伟, 徐浩, 等. 三维-数字减影血管造影技术在肝动脉化学治疗栓塞术中的应用价值探讨. 中华肝脏病杂志, 2018, 26(6): 436-440.
|
36. |
Ladd LM, Tirkes T, Tann M, et al. Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma. Clin Mol Hepatol, 2016, 22(4): 450-457.
|